Glenmark launches Teneligliptin in TS
Glenmark launches Teneligliptin in TS. As part of the phased launching of Teneligliptin in the country, Glenmark Pharmaceuticals Ltd has launched third generation oral anti-diabetic agent, Teneligliptin, used in management of type-2 diabetes mellitus, in Hyderabad and Telangana markets.
An advanced diabetes treatment at affordable cost
Hyderabad: As part of the phased launching of Teneligliptin in the country, Glenmark Pharmaceuticals Ltd has launched third generation oral anti-diabetic agent, Teneligliptin, used in management of type-2 diabetes mellitus, in Hyderabad and Telangana markets.
.jpg)
The molecule, which was developed locally, is being introduced under two brands – Ziten and Zita Plus. Globally, gliptins is considered as preferred line of treatment to manage type-2 diabetes. Announcing launching of these two brands, company’s President, Sujesh Vasudevan revealed, “We are at the final stages to submit data on the combination drug - teneligliptin with metformin.
It will be the second drug from the company to be launched in the area of management of type-2 diabetes.” Teneligliptin was already been launched in Mumbai a month ago and it will be launched across the country in a phased manner, he said. Vasudevan claimed that the drug would benefit the patient about 55 per cent less, compared to other similar drug brands.
“Most gliptins are priced at about Rs 45 per day treatment where as Ziten or Zita Plus would cost Rs 19.90 per day treatment.” After getting approval from DCGI, the company had conducted clinical trials for two years before introducing in to the market. Considering the demand for the medicine in the country and world over, the company is targeting a turnover of about Rs 100 crore for the full year of operations.
On the new launches, Vasudevan said that the company is expecting sizable new introductions from the gliptins stable and targets a major share from Rs 1,200 crore market size. On Capex, Vasudevan said the company plans to invest Rs 600 crore in the current year and a major portion would go in the setting up of the production facility in US at Monroe Corporate Centre, North Carolina.
It will undertake production of oral solid units initially and would expand to injectables and topical. However, he refused to reveal financial details of the project. “The plant is ready for USFDA inspection,” he said hinting that the commercial production may commence before 2018. “Everything will depend on the USFDA approvals,” he pointed out.
